A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Haberin özeti
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Güvenilir yayınların güncel haberlerini kısa açıklamalarıyla takip edin. Ayrıntılar için özgün kaynak bağlantısını açın.